Veterinary World

     Open access and peer reviewed journal  

ISSN (Online): 2231-0916

ISSN (Print): 0972-8988


Home l Editorial board l Instructions for authors l Reviewer guideline l Open access policy l Archives l FAQ

Open Access

Copyright: The authors. This article is an open access article licensed under the terms of the Creative Commons Attribution License

( which permits unrestricted use, distribution and reproduction in any medium, provided the work is properly cited.

Research (Published online: 10-02-2015)

4. Construction and characterization of recombinant human adenovirus type 5 expressing foot-and-mouth disease virus capsid proteins of Indian vaccine strain, O/IND/R2/75 - Ramesh Kumar, B. P. Sreenivasa and R. P. Tamilselvan

Veterinary World, 8(2): 147-155



   doi: 10.14202/vetworld.2015.147-155



Ramesh Kumar: FMD Research Centre, Indian Veterinary Research Institute, Bangalore - 560 024, Karnataka, India;

B. P. Sreenivasa: FMD Research Centre, Indian Veterinary Research Institute, Bangalore - 560 024, Karnataka, India;

R. P. Tamilselvan: FMD Research Centre, Indian Veterinary Research Institute, Bangalore - 560 024, Karnataka, India;


Received: 20-10-2014, Revised: 18-12-2014, Accepted: 27-12-2014, Published online: 10-02-2015


Corresponding author: B. P. Sreenivasa, e-mail:

Citation: Kumar R, Sreenivasa BP, Tamilselvan RP (2015) Construction and characterization of recombinant human adenovirus type 5 expressing foot-and-mouth disease virus capsid proteins of Indian vaccine strain, O/IND/R2/75, Veterinary World, 8(2): 147-155.

Aim: Generation of recombinant human adenovirus type 5 expressing foot-and-mouth disease virus (FMDV) capsid protein genes along with full-length 2B, 3B and 3Cpro and its characterization.

Materials and Methods: FMD viral RNA isolation, cDNA synthesis, and polymerase chain reaction were performed to synthesize expression cassettes (P1-2AB3BCwt and P1-2AB3BCm) followed by cloning in pShuttle-CMV vector. Chemically competent BJ5183-AD-1 cells were transformed with the recombinant pShuttle-CMV to produce recombinant adenoviral plasmids. HEK-293 cells were transfected with the recombinant adenoviral plasmids to generate recombinant adenoviruses (hAd5/P1-2AB3BCwt and hAd5/P1-2AB3BCm). Expression of the target proteins was analyzed by sandwich ELISA and indirect immunofluorescence assay. The recombinant adenoviruses were purified and concentrated by CsCl density gradient ultracentrifugation. Growth kinetics and thermostability of the recombinant adenoviruses were compared with that of non-recombinant replication-defective adenovirus (dAd5).

Results: The recombinant adenoviruses containing capsid protein genes of the FMDV O/IND/R2/75 were generated and amplified in HEK-293 cells. The titer of the recombinant adenoviruses was approximately 108, 109.5 and 1011 TCID50/ml in supernatant media, cell lysate and CsCl purified preparation, respectively. Expression of the FMDV capsid protein was detectable in sandwich ELISA and confirmed by immunofluorescence assay. Growth kinetics of the recombinant adenoviruses did not reveal a significant difference when compared with that of dAd5. A decrement of up to 10-fold at 4C and 21-fold at 37C was recorded in the virus titers during 60 h incubation period and found to be statistically significant (p<0.01).

Conclusion: Recombinant adenoviruses expressing capsid proteins of the FMDV O/IND/R2/75 were constructed and produced in high titers. In vitro expression of the target proteins in the adenovirus vector system was detected by sandwich ELISA and immunofluorescence assay.

Keywords: foot-and-mouth disease, growth kinetics, recombinant hAd5, thermostability, virus-like particles.

1. Grubman, M.J. and Baxt, B. (2004) Foot- and- mouth disease. Clin. Microbiol. Rev., 17: 465-493.
PMid:15084510 PMCid:PMC387408
2. Sobrino, F., Saiz, M., Jimmenez-Clavero, M.A., Nunez, J.I., Rosas, M.F., Baranowsky, E. and Ley, V. (2001) Foot- and- mouth disease virus: A long known virus, but a current threat. Vet. Res., 32(1): 1-30.
3. FAO. (2012) Foot- and- Mmouth Ddisease. OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 6th ed Paris, FranceOIE Terrestrial Manual. ???, FAO(2012) Foot and Mouth Disease.
4. Charleston, B., Bankowski, B., Gubbins, S., Chase-Topping, M.E., Schley, D., Howey, R., Barnett, P.V., Gibson, D., Juleff, N.D. and Woolhouse, M.E.J. (2011) Relationship between clinical symptoms and transmission of an infectious disease and the implications for control. Science., 332(6030): 726-729.
5. Rueckert, R.R. (1996) Picornaviridae: The viruses and their replication. In: Fields, B.N., Knipe, D.M., Howley, P.H., Chanock, R.M., Melnick, J.L., Monath, T.P., Roizman, B. and Straus S.E. editors. Fields Virology. 3rd ed., Philadelphia, PA, Lippincott-Raven. p609-654.
6. Pilipenko, E.V., Maslova, S.V., Sinyakov, A.N. and Agol, V.I. (1992a) Towards identification of cis-acting elements involved in the replication of enterovirus and rhinovirus RNAs: a proposal for the existence of tRNA-like terminal structures. Nucleic. Acids. Res., 20(7): 1739-1745.
PMid:1315956 PMCid:PMC312265
7. Anon (2010) Annual Report (2009-2010). Project Directorate on Foot and Mouth Disease. Mukteswar, India.
8. Geale, D.W., Barnett, P.V., Clarke, G.W., Davis, J. and Kasar, T.R. (2013) A review of OIE country status recovery using vaccinate to live versus vaccinate to die foot- and- mouth disease response policies II: Waiting periods after emergency vaccination in FMD free countries. Transbound. Emerg. Dis., doi:10.1111/tbed.12165.
9. Jennings, G.T. and Bachmann, M.F. (2008) The coming of age of virus-like particle vaccines. Biol. Chem., 389(5): 521-536.
10. Plummer, E.M. and Manchester, M. (2011) Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol., 3(2): 174-196.
11. Abrams, C.C., King, A.M, and Belsham, G.J. (1995) Assembly of foot- and- mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J. Gen. Virol., 76: 3089-3098.
12. Mason, P.W., Chinsangaram, J., Moraes, M.P., Mayr, G.A. and Grubman, M.J. (2003) Engineering better vaccines for foot- and- mouth disease. Dev. Biol., 114: 79-88.
13. Lewis, S.A., Morgan, D.O. and Grubman, M.J. (1991) Expression, processing, and assembly of foot- and- mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J. Virol., 65(12): 6572-6580.
PMid:1658362 PMCid:PMC250715
14. Li, Z., Yi, Y., Yin, X., Zhang, Z. and Liu, J. (2008) Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PloS One., 3(5): e2273.
PMid:18509464 PMCid:PMC2386233
15. Rweyemamu, M.M., Terry, G. and Pay, T.W. (1979) Stability and immunogenicity of empty particles of foot- and- mouth disease virus. Arch. Virol., 59(1-2): 69-79.
16. Guo, C., Zhang, C., Zheng, H. and Huang, Y. (2013) Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice. Res. Vet. Sci., 95(2): 736-741.
17. Mayr, G.A., Chinsangaram, J. and Grubman, M.J. (1999) Development of replication-deficient adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology., 263(2): 496-506.
18. Kushnir, N., Streatfield, S. and Yusibov, V. (2012) Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine., 31(1): 58-83.
19. Silva, A.C., Fernades, P., Sousa, M.F. and Alves, P.M. (2014) Scalable production of adenovirus vectors. Methods. Mol. Biol., 1089: 175-196.
20. Wald, W.S. and Toth, K. (2014) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr. Gene. Ther., 13(6): 421-433.
21. Luo, J., Deng, Z.L., Luo, X., Tang, N., Song, W.X., Chen, J., Sharff, KA., Luu, HH., Haydon, RC., Kinzler, KW., Vogelstein, B., He, TC. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc., 2(5): 1236-1247.
22. Deal, C., Pekosz, A. and Ketner, G. (2013) Prospects for oral replicating adenovirus-vectored vaccines. Vaccine, 31(32): 3236-3243.
PMid:23707160 PMCid:PMC3750733
23. Odondo, B.O. (2014) The influence of delivery vectors on HIV vaccine efficacy. Front. Microbiol., 5: 439.
24. Brake, D.A., McIlhaney, M., Miller, T., Christianson, K., Keene, A., Lohnas, G., Purcell, C., Neilan, J., Schutta, C., Barrera, J., Burrage, T., Brough, DE. and Butman, BT. (2012) Human adenovirus vectored foot- and- mouth disease vaccines: establishment of a vaccine product profile through in vitro testing. Dev. Biol., 134: 123-133.
25. Romanutti, C., D'Antuono, A., Palacios, C., Quattrocchi, V., Zamorano, P., La Torre, J. and, Mattion, N. (2013) Evaluation of the immune response elicited by vaccination with viral vectors encoding FMDV capsid proteins and boosted with inactivated virus. Vet. Microbiol., 165(3-4): 333-340.
26. Lu, Z., Bao, H., Cao, Y., Sun, P., Guo, J., Li, P., Bai, X., Chen, Y., Xie, B., Li, D., Liu, Z., and Xie, Q. (2008) Protection of guinea pigs and swine by a recombinant adenovirus expressing O serotype of foot- and- mouth disease virus whole capsid and 3C protease. Vaccine, 26 (Suppl 6): G48-53.
27. Pacheco, J.M., Brum, M.C., Moraes, M.P., Golde, W.T. and Grubman, M.J. (2005) Rapid protection of cattle from direct challenge with foot- and- mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology., 337(2): 205-209.
28. Pena, L., Moraes, M.P., Koster, M., Burrage, T., Pacheco, J.M., Segundo, F.D. and Grubman, M.J. (2008) Delivery of a foot- and- mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine, 26(45): 5689-5699.
29. Moraes, M.P., Segundo, F.D., Dias, C.C., Pena, L. and Grubman, M.J. (2011) Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine, 29(51): 9431-9440.
30. Sambrook J. and Russel D.W. (2001) Molecular Cloning: A Laboratory Manual. 3rd ed. New York, Cold Spring Harbor. p1.-117.
31. Reed, L.J. and Muench, H. (1938) A simple method for estimation of fifty percent end point. Am. J. Hyg., 27(3): 493-497.
32. Golde, W.T., Pacheco, J.M., Duque, H., Doel, T., Penfold, B., Ferman, G.S., Gregg, D.R. and Rodriguez, L.L. (2005) Vaccination against foot- and- mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response. Vaccine., 23(50): 5775-5782.
33. Sanz-Parra, A., Jimenez-Clavero, M.A., Garcia-Briones, M.M., Blanco, E., Sobrino, F. and Ley, V. (1999) Recombinant viruses expressing the foot- and- mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology., 259(1): 129-134.
34. Korrapati, A.B., Swaminathan, G., Singh, A., Khanna, N. and Swaminathan, S. (2012) Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses. PLoS. Negl. Trop. Dis., 6(7): e1735.
35. Barouch, D.H. and Picker, L.J. (2014) Novel vaccine vectors for HIV-1. Nat. Rev. Microbiol., 12(11): 765-771. doi: 10.1038/nrmicro3360.
36. Bette, A., Prevec, L. and Graham, F. (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol., 67(10): 5911-5921.
37. Saha, B., Wong, C.M. and Parks, R.J. (2014) The Adenovirus genome contributes to the structural stability of the virion. Viruses, 6(9): 3563-3583.
PMid:25254384 PMCid:PMC4189039
38. Porta, C., Xu, X., Loureiro, S., Paramasivam, S., Ren, J., Al-Khalil, T., Burman, A., Jackson, T., Belsham, GJ., Curry, S., Lomonossoff, GP., Parida, S., Paton, D., Li, Y., Wilsden, G., Ferris, N., Owens, R., Kotecha, A., Fry, E., Stuart, DI., Charleston, B. and Jones, IM. (2013) Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. J. Virol. Methods., 187(2): 406-412.
PMid:23174161 PMCid:PMC3558679
39. Torres, J.M., Alonso, C., Ortega, A., Mittal, S., Graham, F. and Enjuanes, L. (1996) Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J. Virol., 70(6): 3770-3780.
PMid:8648712 PMCid:PMC190253
40. Xue, C., Tian, X., Li, X., Zhou, Z., Su, X. and Zhou, R. (2014) Construction and characterization of a recombinant adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon. Virus. Res., 183: 67-74.
41. Hehir, K.M., Armentano, D., Cardoza, L.M., Choquette, T.L., Berthelette, P.B., White, G.A., Couture, L.A., Everton, M.B., Keegan, J., Martin, J.M., Pratt, D.A., Smith, M.P., Smith, A.E., Wadsworth, S.C. (1996) Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol., 70(12): 8459-8467.
PMid:8970968 PMCid:PMC190936
42. Liu, J., Nian, QG., Zhang, Y., Xu, LJ., Hu, Y., Li, J., Deng, YQ., Zhu, SY., Wu, XY., Qin, ED., Jiang, T. and, Qin, CF. (2014) In vitro characterization of human adenovirus type 55 in comparison with its parental adenoviruses, types 11 and 14. PLoS One, 9(6): e100665.
PMid:24956280 PMCid:PMC4067339